

Alexander W Tarr

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7664275/alexander-w-tarr-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

67

papers

2,853

citations

27

h-index

53

g-index

80

ext. papers

3,291

ext. citations

7.2

avg, IF

4.7

L-index

#	Paper	IF	Citations
67	The HCV Envelope Glycoprotein Down-Modulates NF-B Signalling and Associates With Stimulation of the Host Endoplasmic Reticulum Stress Pathway.. <i>Frontiers in Immunology</i> , 2022 , 13, 831695	8.4	
66	Immunocompromised children and young people are at no increased risk of severe COVID-19. <i>Journal of Infection</i> , 2021 ,	18.9	5
65	An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development. <i>Gastroenterology</i> , 2021 ,	13.3	2
64	Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2021 , 13, eabj0847	17.5	16
63	Liver-expressed and limit hepatitis C virus cross-species transmission to mice. <i>Science Advances</i> , 2020 , 6,	14.3	9
62	Human Bocavirus infection and respiratory tract disease identified in a UK patient cohort. <i>Journal of Clinical Virology</i> , 2020 , 129, 104453	14.5	7
61	Nanopore sequencing from extraction-free direct PCR of dried serum spots for portable hepatitis B virus drug-resistance typing. <i>Journal of Clinical Virology</i> , 2020 , 129, 104483	14.5	4
60	Hepatitis C Virus Vaccine: Challenges and Prospects. <i>Vaccines</i> , 2020 , 8,	5.3	24
59	Perceptions and Experiences of the University of Nottingham Pilot SARS-CoV-2 Asymptomatic Testing Service: A Mixed-Methods Study. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 18,	4.6	15
58	Rationally derived inhibitors of hepatitis C virus (HCV) p7 channel activity reveal prospect for bimodal antiviral therapy. <i>ELife</i> , 2020 , 9,	8.9	3
57	Enterovirus subtyping in a routine UK laboratory setting between 2013 and 2017. <i>Journal of Clinical Virology</i> , 2020 , 132, 104646	14.5	0
56	Interferon-Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection. <i>Hepatology</i> , 2019 , 70, 1506-1520	11.2	11
55	Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance. <i>Journal of Hepatology</i> , 2019 , 71, 14-24	13.4	12
54	Elevated serum activity of MBL and ficolin-2 as biomarkers for progression to hepatocellular carcinoma in chronic HCV infection. <i>Virology</i> , 2019 , 530, 99-106	3.6	5
53	Cloning and Analysis of Authentic Patient-Derived HCV E1/E2 Glycoproteins. <i>Methods in Molecular Biology</i> , 2019 , 1911, 275-294	1.4	3
52	InFusion Cloning for the Generation of Biologically Relevant HCV Chimeric Molecular Clones. <i>Methods in Molecular Biology</i> , 2019 , 1911, 93-104	1.4	1
51	Expression of human ficolin-2 in hepatocytes confers resistance to infection by diverse hepatotropic viruses. <i>Journal of Medical Microbiology</i> , 2019 , 68, 642-648	3.2	1

50	Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. <i>Journal of Hepatology</i> , 2019 , 70, 593-602	13.4	11
49	Enhanced nanoparticle uptake into virus infected cells: Could nanoparticles be useful in antiviral therapy?. <i>International Journal of Pharmaceutics</i> , 2018 , 547, 572-581	6.5	20
48	Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies. <i>Antiviral Research</i> , 2018 , 160, 25-37	10.8	4
47	Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge. <i>Antiviral Research</i> , 2017 , 143, 48-61	10.8	5
46	How have retrovirus pseudotypes contributed to our understanding of viral entry?. <i>Future Virology</i> , 2017 , 12, 569-581	2.4	
45	High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease. <i>Journal of Hepatology</i> , 2017 , 66, 28-38	13.4	17
44	Technical considerations for the generation of novel pseudotyped viruses. <i>Future Virology</i> , 2016 , 11, 47-59	2.4	9
43	Flexible and rapid construction of viral chimeras applied to hepatitis C virus. <i>Journal of General Virology</i> , 2016 , 97, 2187-2193	4.9	11
42	Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay. <i>Journal of General Virology</i> , 2016 , 97, 2265-2279	4.9	30
41	Hepatitis C virus quasispecies and pseudotype analysis from acute infection to chronicity in HIV-1 co-infected individuals. <i>Virology</i> , 2016 , 492, 213-24	3.6	3
40	Human lectins and their roles in viral infections. <i>Molecules</i> , 2015 , 20, 2229-71	4.8	62
39	Non-ionic detergents facilitate non-specific binding of M13 bacteriophage to polystyrene surfaces. <i>Journal of Virological Methods</i> , 2015 , 221, 1-8	2.6	7
38	Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies. <i>Journal of Virology</i> , 2015 , 89, 2170-81	6.6	62
37	A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance. <i>Journal of Virology</i> , 2015 , 90, 3288-301	6.6	47
36	Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. <i>Viruses</i> , 2015 , 7, 3995-4046	6.2	38
35	The past, present and future of neutralizing antibodies for hepatitis C virus. <i>Antiviral Research</i> , 2014 , 105, 100-11	10.8	95
34	Colicin import into E. coli cells: a model system for insights into the import mechanisms of bacteriocins. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014 , 1843, 1717-31	4.9	32
33	B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins. <i>Blood</i> , 2014 , 123, 1512-5	2.2	34

32	Type I interferon rapidly restricts infectious hepatitis C virus particle genesis. <i>Hepatology</i> , 2014 , 60, 1891-1901	4
31	Recombinant human L-ficolin directly neutralizes hepatitis C virus entry. <i>Journal of Innate Immunity</i> , 2014 , 6, 676-84	6.9 25
30	Analysis of serine codon conservation reveals diverse phenotypic constraints on hepatitis C virus glycoprotein evolution. <i>Journal of Virology</i> , 2014 , 88, 667-78	6.6 2
29	The P body protein LSM1 contributes to stimulation of hepatitis C virus translation, but not replication, by microRNA-122. <i>Nucleic Acids Research</i> , 2014 , 42, 1257-69	20.1 19
28	Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation. <i>Journal of Biological Chemistry</i> , 2014 , 289, 35015-28	5.4 12
27	An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. <i>Hepatology</i> , 2013 , 58, 932-9	11.2 56
26	Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies. <i>Clinical and Developmental Immunology</i> , 2013 , 2013, 450963	37
25	The role of neutralizing antibodies in hepatitis C virus infection. <i>Journal of General Virology</i> , 2012 , 93, 1-19	4.9 51
24	The role of humoral innate immunity in hepatitis C virus infection. <i>Viruses</i> , 2012 , 4, 1-27	6.2 32
23	Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host. <i>Journal of Virology</i> , 2012 , 86, 11956-66	6.6 30
22	Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. <i>Journal of Virology</i> , 2012 , 86, 2739-49	6.6 48
21	Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype. <i>Journal of Virology</i> , 2011 , 85, 4246-57	6.6 46
20	Identification of new functional regions in hepatitis C virus envelope glycoprotein E2. <i>Journal of Virology</i> , 2011 , 85, 1777-92	6.6 62
19	Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. <i>Protein and Cell</i> , 2010 , 1, 664-74	7.2 48
18	Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. <i>Nature Medicine</i> , 2008 , 14, 25-7	50.5 466
17	Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 339-45	3.4 5
16	Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. <i>Journal of Virology</i> , 2008 , 82, 1047-52	6.6 110
15	Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. <i>Journal of General Virology</i> , 2008 , 89, 653-659	4.9 121

14	Cloning, expression, and functional analysis of patient-derived hepatitis C virus glycoproteins. <i>Methods in Molecular Biology</i> , 2007 , 379, 177-97	1.4	24
13	Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 16269-74	11.5	115
12	Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. <i>Journal of General Virology</i> , 2007 , 88, 2991-3001	4.9	56
11	Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes. <i>Journal of General Virology</i> , 2007 , 88, 458-469	4.9	23
10	Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. <i>Hepatology</i> , 2006 , 43, 592-601	11.2	132
9	Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. <i>Journal of Virology</i> , 2006 , 80, 8695-704	6.6	204
8	Tagged polymerase chain reaction subtractive hybridization for the enrichment of phage display random peptide libraries. <i>Analytical Biochemistry</i> , 2005 , 339, 61-8	3.1	1
7	Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. <i>Hepatology</i> , 2005 , 41, 265-74	11.2	221
6	Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. <i>Journal of Virology</i> , 2005 , 79, 11095-104	6.6	234
5	Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets. <i>Journal of General Virology</i> , 2005 , 86, 2507-2512	4.9	26
4	Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection. <i>Journal of General Virology</i> , 2005 , 86, 1931-1942	4.9	33
3	Potent anti-SARS-CoV-2 Antibody Responses are Associated with Better Prognosis in Hospital Inpatient COVID-19 Disease		1
2	Rationally derived inhibitors of hepatitis C virus (HCV) p7 channel activity reveal prospect for bimodal antiviral therapy		1
1	Extraction-free direct PCR from dried serum spots permits HBV genotyping and RAS identification by Sanger and minION sequencing		2